Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

One out of the three major indices are trading lower today with the

Dow Jones Industrial Average

(

^DJI

) trading down 2 points (0.0%) at 17,750 as of Thursday, July 30, 2015, 1:05 PM ET. The NYSE advances/declines ratio sits at 1,461 issues advancing vs. 1,490 declining with 187 unchanged.

The Drugs industry currently sits down 0.7% versus the S&P 500, which is unchanged. Top gainers within the industry include

Grifols

(

GRFS

), up 5.0%,

GlaxoSmithKline

(

GSK

), up 1.9%,

Gilead

(

GILD

), up 1.9% and

Biogen

(

BIIB

), up 1.7%. On the negative front, top decliners within the industry include

Novo Nordisk A/S

(

NVO

), down 1.8%,

Teva Pharmaceutical Industries

(

TEVA

), down 1.4%,

Eli Lilly and

(

LLY

), down 0.7%,

AbbVie

(

ABBV

), down 0.5% and

Novartis

(

NVS

), down 0.5%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3.

Sanofi

(

SNY

) is one of the companies pushing the Drugs industry higher today. As of noon trading, Sanofi is up $0.78 (1.5%) to $53.42 on light volume. Thus far, 467,222 shares of Sanofi exchanged hands as compared to its average daily volume of 1.7 million shares. The stock has ranged in price between $52.46-$53.44 after having opened the day at $52.84 as compared to the previous trading day's close of $52.64.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Sanofi researches, develops, and markets various therapeutic solutions. Sanofi has a market cap of $142.0 billion and is part of the health care sector. Shares are up 15.4% year-to-date as of the close of trading on Wednesday. Currently there are 2 analysts who rate Sanofi a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates

Sanofi

as a

buy

. The company's strengths can be seen in multiple areas, such as its expanding profit margins and increase in stock price during the past year. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full

Sanofi Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

2. As of noon trading,

AstraZeneca

(

AZN

) is up $0.86 (2.6%) to $33.88 on average volume. Thus far, 1.2 million shares of AstraZeneca exchanged hands as compared to its average daily volume of 2.7 million shares. The stock has ranged in price between $33.48-$33.90 after having opened the day at $33.71 as compared to the previous trading day's close of $33.01.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

AstraZeneca PLC engages in the discovery, development, and commercialization of prescription medicines for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection, and neuroscience diseases worldwide. AstraZeneca has a market cap of $82.9 billion and is part of the health care sector. Shares are down 6.2% year-to-date as of the close of trading on Wednesday. Currently there are 3 analysts who rate AstraZeneca a buy, 1 analyst rates it a sell, and 2 rate it a hold.

TheStreet Ratings rates

AstraZeneca

as a

buy

. The company's strengths can be seen in multiple areas, such as its increase in net income, largely solid financial position with reasonable debt levels by most measures, expanding profit margins and growth in earnings per share. We feel its strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full

AstraZeneca Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

1. As of noon trading,

Vertex Pharmaceuticals

(

VRTX

) is up $5.91 (4.7%) to $131.53 on heavy volume. Thus far, 1.4 million shares of Vertex Pharmaceuticals exchanged hands as compared to its average daily volume of 1.5 million shares. The stock has ranged in price between $121.15-$132.20 after having opened the day at $126.09 as compared to the previous trading day's close of $125.62.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Vertex Pharmaceuticals Incorporated engages in discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases in specialty markets. Vertex Pharmaceuticals has a market cap of $31.3 billion and is part of the health care sector. Shares are up 5.7% year-to-date as of the close of trading on Wednesday. Currently there are 8 analysts who rate Vertex Pharmaceuticals a buy, no analysts rate it a sell, and 9 rate it a hold.

TheStreet Ratings rates

Vertex Pharmaceuticals

as a

sell

. The company's weaknesses can be seen in multiple areas, such as its disappointing return on equity and weak operating cash flow. Get the full

Vertex Pharmaceuticals Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF

(

XPH

) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech

(

BIS

).